Overview

Safety, Tolerability and Efficacy Study With a Fixed-Dose Combination (FDC) Ketoprofen Plus Omeprazole

Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
Primary Objective: To confirm the safety and tolerability of the fixed dose combination of a Non-Steroidal Anti-Inflammatory Drug (NSAID), ketoprofen, associated to a Proton Pump Inhibitor (PPI), omeprazole, in Mexican patients. Secondary Objective: To confirm the efficacy of the combination: - Relief of pain (Visual Analyzed Score (VAS)) - Patients global assessment of disease activity, scored as a scale of 1 (no limitation of normal activities) to 5 (inability to carried out all normal activities)
Phase:
Phase 3
Details
Lead Sponsor:
Sanofi
Treatments:
Ketoprofen
Omeprazole